What is the potential of circulating tumor cells (CTCs) as a marker for cancer?

Susanne Osanto

Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the clinical utility of circulating tumor cells (CTCs) at the European Association of Urology (EAU) conference 2017 in London, UK. She argues that this is a very powerful approach, which allows patients with metastatic disease to be tested for disease presence and the number of circulating cells, as well as the characteristics of the tumor cells. Prof. Osanto explains how circulating tumor cells can be molecularly profiled at a single-cell level.

Share this video  
Similar topics
Related videos
1:17
The reality of implementing TKI therapies for NSCLC in Europe
Silvia Novello
0:43
Mesothelioma: the key unanswered question
Dean Fennell
0:57
Identifying which patients should receive which therapy for lung cancer
Keith Kerr
3:16
Impact of new TKIs on NSCLC treatment planning
Nicolas Girard
1:59
Pembrolizumab in the treatment of head and neck cancer: is there more to the story?
Jean-Pascal Machiels
EAU 2017
Interview
25th March 2017
More from Susanne Osanto
Current landscape and future direction in systemic therapy for renal cell carcinoma (RCC)
Clinical implications of CTCs in prostate cancer – are they the best thing to measure?
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals